UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 4,260 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 441,098 shares of the medical research company’s stock after buying an additional 4,260 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Bio-Rad Laboratories were worth $147,583,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Capital Advisors Ltd. LLC grew its stake in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares during the period. Gladius Capital Management LP bought a new stake in Bio-Rad Laboratories in the third quarter valued at about $32,000. Headlands Technologies LLC bought a new position in Bio-Rad Laboratories during the second quarter worth about $51,000. Finally, Quarry LP bought a new position in Bio-Rad Laboratories during the second quarter worth about $59,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Royal Bank of Canada increased their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price on the stock. Citigroup lifted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $340.53 on Friday. The firm’s 50 day moving average price is $340.77 and its two-hundred day moving average price is $317.76. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The firm has a market cap of $9.53 billion, a P/E ratio of -12.46 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same period in the prior year, the business earned $2.33 EPS. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP James Barry sold 623 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.